W. Fukuokaya

发表

Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents.

S. Egawa, H. Sasaki, M. Honda, 2019, Clinical genitourinary cancer.

Laparoscopic partial nephrectomy for the horseshoe kidney with indocyanine green fluorescence guidance under the modified supine position

S. Egawa, Shunsuke Tsuzuki, J. Miki, 2022, IJU case reports.

Blood platelet volume predicts treatment-specific outcomes of metastatic castration-resistant prostate cancer

S. Egawa, H. Sasaki, Shunsuke Tsuzuki, 2020, International Journal of Clinical Oncology.

Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.

S. Egawa, W. Fukuokaya, 2020, European urology.

Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.

G. Gandaglia, S. Shariat, S. Egawa, 2022, European urology.

Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis

S. Shariat, S. Egawa, W. Krajewski, 2022, World Journal of Urology.

Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma

Shunsuke Tsuzuki, Fumihiko Urabe, Kagenori Ito, 2022, Cancer Immunology, Immunotherapy.

Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma

S. Egawa, Masatoshi Tanaka, Shunsuke Tsuzuki, 2021, Cancer Immunology, Immunotherapy.

Modified Glasgow prognostic score is a pre-surgical prognostic marker of disease mortality in upper urinary tract urothelial carcinoma.

S. Egawa, Shunsuke Tsuzuki, J. Miki, 2020, Japanese journal of clinical oncology.

Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab

K. Takahara, R. Shiroki, H. Azuma, 2022, Cancers.

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

K. Takahara, R. Shiroki, H. Azuma, 2022, Clinical and translational radiation oncology.

Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan

S. Egawa, Tomohito Tanaka, H. Uehara, 2021, Cancers.

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

S. Egawa, Tomohito Tanaka, H. Uehara, 2021, Cancers.

Bladder cancer invasion along a tension‐free vaginal mesh

A. Ochi, K. Honma, T. Huang, 2021, IJU case reports.

Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer

S. Egawa, H. Sasaki, K. Mori, 2019, International Journal of Clinical Oncology.

Prognostic role of the systemic immune–inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration

V. Margulis, A. Briganti, S. Shariat, 2021, Cancer Immunology, Immunotherapy.

Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer

K. Akakura, M. Inoue, H. Kurosaki, 2018, International Journal of Clinical Oncology.

Risk stratification for the prediction of overall survival could assist treatment decision‐making at diagnosis of castration‐resistant prostate cancer: a multicentre collaborative study in Japan

S. Egawa, Tomohito Tanaka, H. Uehara, 2020, BJU international.

Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.

Hiroyuki Takahashi, S. Egawa, S. Hirooka, 2021, The Journal of urology.

Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.

S. Egawa, T. Kamoto, N. Terada, 2022, Urologic oncology.

Docetaxel versus abiraterone for metastatic hormone‐sensitive prostate cancer with focus on efficacy of sequential therapy

S. Shariat, T. Habuchi, C. Ohyama, 2023, The Prostate.

Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.

S. Egawa, Tomohito Tanaka, H. Uehara, 2022, Urologic oncology.

Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer

Y. Hirose, S. Egawa, Tomohito Tanaka, 2022, Journal for ImmunoTherapy of Cancer.

Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab

S. Egawa, Masatoshi Tanaka, Shunsuke Tsuzuki, 2020 .

Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer

S. Egawa, Shunsuke Tsuzuki, K. Mori, 2021, The Prostate.

Supine extraperitoneal laparoscopic nephroureterectomy without patient repositioning

S. Egawa, Shunsuke Tsuzuki, K. Mori, 2020, International journal of urology : official journal of the Japanese Urological Association.

Differences in sex hormone recovery profile after cessation of 12‐week gonadotropin‐releasing hormone antagonist versus agonist therapy

Hiroyuki Takahashi, S. Egawa, H. Sasaki, 2021, Andrology.

Metformin treatment ameliorates diabetes‐associated decline in hippocampal neurogenesis and memory via phosphorylation of insulin receptor substrate 1

M. Nakazato, H. Takeuchi, D. Tanokashira, 2018, FEBS open bio.

Percutaneous cryoablation versus partial nephrectomy for cT1b renal tumors: An inverse probability weight analysis.

Shunsuke Tsuzuki, S. Sadaoka, J. Miki, 2023, Urologic oncology.

Involvement of insulin receptor substrates in cognitive impairment and Alzheimer’s disease

D. Tanokashira, W. Fukuokaya, Akiko Taguchi, 2019, Neural regeneration research.

The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy

S. Egawa, Shunsuke Tsuzuki, J. Miki, 2021, International Journal of Clinical Oncology.

Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis

S. Shariat, S. Egawa, W. Krajewski, 2022, World Journal of Urology.

Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma

T. Adachi, S. Egawa, K. Takahara, 2022, BJU international.

Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.

S. Egawa, Shunsuke Tsuzuki, Masayuki Tomita, 2021, Japanese journal of clinical oncology.

Functional and oncological outcome of percutaneous cryoablation versus laparoscopic partial nephrectomy for clinical T1 renal tumors: A propensity score-matched analysis.

S. Egawa, H. Sasaki, K. Mori, 2020, Urologic oncology.

Red cell distribution width predicts time to recurrence in patients with primary non-muscle-invasive bladder cancer and improves the accuracy of the EORTC scoring system.

A. Ochi, S. Egawa, J. Miki, 2020, Urologic oncology.

Effectiveness of Intravesical Doxorubicin Immediately Following Resection of Primary Non-muscle-invasive Bladder Cancer: A Propensity Score-matched Analysis.

A. Ochi, S. Egawa, J. Miki, 2020, Clinical genitourinary cancer.

En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis

Hiroyuki Takahashi, S. Shariat, Shunsuke Tsuzuki, 2023, Annals of Surgical Oncology.

Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma

S. Egawa, Masatoshi Tanaka, Shunsuke Tsuzuki, 2021, Targeted Oncology.

Reply to Cengiz Beyan and Esin Beyan. Mean platelet volume may not be a significant prognostic factor in patients with metastatic castration-resistant prostate cancer. Int J Clin Oncol 97(2), 3–4, 2020

S. Egawa, H. Sasaki, Shunsuke Tsuzuki, 2020, International Journal of Clinical Oncology.

Incidental Prostate Cancer in Radical Cystoprostatectomy Specimens is Associated with Worse Overall Survival

Hiroyuki Takahashi, S. Egawa, Shun Sato, 2021 .

Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials.

K. Akazawa, K. Mori, T. Yanagisawa, 2023, Prostate cancer and prostatic diseases.

Two‐step technique of early adrenal artery ligation in open adrenalectomy of giant right adrenal pheochromocytomas: Three case reports

A. Ochi, Y. Kitagawa, Koichiro Suzuki, 2018, IJU case reports.

Comparison of Quality of Life and Injection Site Reactions After Switching from Degarelix 80 mg to 480 mg in Advanced Prostate Cancer: A Prospective Trial

J. Miki, T. Yanagisawa, K. Obayashi, 2023, AntiCancer Research.

Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.

K. Takahara, R. Shiroki, Shunsuke Tsuzuki, 2023, Cancer medicine.

Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate

Shunsuke Tsuzuki, K. Mori, Fumihiko Urabe, 2024, JAMA network open.

Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.

Shunsuke Tsuzuki, K. Mori, Fumihiko Urabe, 2024, International journal of clinical oncology.

Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer.

Shunsuke Tsuzuki, K. Mori, Fumihiko Urabe, 2024, Clinical genitourinary cancer.

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.

K. Takahara, R. Shiroki, H. Azuma, 2023, Clinical genitourinary cancer.

Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.

R. Saito, N. Nishiyama, Fumihiko Urabe, 2024, International journal of urology : official journal of the Japanese Urological Association.

Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction

K. Mori, Fumihiko Urabe, T. Yanagisawa, 2024, Cureus.

Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world.

K. Mori, Kagenori Ito, Yusuke Koike, 2024, International urology and nephrology.

Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis

K. Mori, Yusuke Koike, J. Miki, 2023, International journal of clinical oncology.

Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.

Shunsuke Tsuzuki, Fumihiko Urabe, K. Hata, 2024, Japanese journal of clinical oncology.

Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data

K. Mori, P. Rajwa, E. Laukhtina, 2024, Cancer immunology, immunotherapy : CII.

Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.

R. Shiroki, K. Komura, T. Inamoto, 2024, Targeted oncology.

Perioperative renal function change and oncological outcomes of radical nephroureterectomy in patients with upper tract urothelial carcinoma: A multicenter retrospective study.

Takaya Sasaki, Shunsuke Tsuzuki, K. Mori, 2024, Urologic oncology.

Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.

Shunsuke Tsuzuki, K. Mori, Fumihiko Urabe, 2024, International journal of urology : official journal of the Japanese Urological Association.

Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta‐analysis

A. Cimadamore, M. Moschini, B. Pradère, 2023, International journal of urology : official journal of the Japanese Urological Association.